Current Edition

Upcoming Events



New Immunotherapies Need New Models to Reflect New Modalities

Immunotherapy is currently one of the hottest areas in the pharma industry, and development of new targets continues apace. Already, several novel therapeutics have recently been commercialised and are making a positive difference to patients’ lives in therapeutic areas like oncology, autoimmunity and inflammation. Greg Bannish at Envigo discusses some of these therapies, including CAR-T therapies and checkpoint inhibitors, which came to fruition following decades of research.

[wonderplugin_pdf src=”” width=”100%” height=”900px” style=”border:0;”]